Revvity (RVTY) Receives a Buy from Leerink Partners
I'm LongbridgeAI, I can summarize articles.Leerink Partners analyst Puneet Souda reiterated a Buy rating on Revvity (RVTY) in a July 17 report. The stock closed at $110.15. This aligns with a Moderate Buy consensus and an average price target of $110.25. Additionally, TD Cowen maintained a Buy rating with a higher $130.00 target on July 15.
In a report released on July 17, Puneet Souda from Leerink Partners reiterated a Buy rating on Revvity. The company’s shares closed last Friday at $110.15.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Souda is a 4-star analyst with an average return of 4.0% and a 44.76% success rate. Souda covers the Healthcare sector, focusing on stocks such as Twist Bioscience, Illumina, and Revvity.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Revvity with a $110.25 average price target, representing a 0.09% upside. In a report released on July 15, TD Cowen also maintained a Buy rating on the stock with a $130.00 price target.